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Introduction: Probucol (PB) and cilostazol (CZ) both exhibit anti-atherogenic effects. However, their combinato-
rial effects are unclear. This study was designed to investigate their combinatorial anti-atherogenic effect in
cholesterol-fed rabbits.
Materials and Methods: Rabbits were fed a cholesterol diet with PB or CZ alone or both PB and CZ for 16 weeks.
The plasma levels of total cholesterol, LDL-cholesterol, HDL-cholesterol, C-reactive protein, superoxide
dismutase, malondialdehyde, and nitric oxide (NO) were measured. The aortic atherosclerotic lesions were
grossly andmicroscopically evaluated. Additionally, in vitro experimentswere conducted using human umbilical
vein endothelial cells.
Results and Conclusion: We found that the PB group and the PB + CZ group exhibited a reduction in the lesion
areas (70% in the PB + CZ group, 56% in the PB group) compared with the vehicle group. However, although
PB alone and PB + CZ led to a reduction in the lesion size, the histological analysis revealed that only PB + CZ
signiﬁcantly decreased the macrophage accumulation and smooth muscle cell proliferation in the lesions com-
pared with the vehicle group. The plasma levels of total cholesterol in the PB + CZ group were decreased com-
pared with the vehicle group, Moreover, PB + CZ exerted obvious anti-oxidant and anti-inﬂammatory effects.
Interestingly, the PB + CZ treatment led to amarked increase in the levels of plasmaNO. The in vitro experiments
showed that the combinatorial treatment up-regulated the levels of NO and protein S-nitrosylation in endothelial
cells treated with oxidized LDL. In summary, these results suggest that PB and CZ exert combinatorial anti-
atherogenic effects.© 2013 The Authors. Published by Elsevier Ltd.Open access under CC BY-NC-SA license. Introduction
Atherosclerosis is a major cause of mortality in both developed and
developing countries [1], and hypercholesterolemia is an important
risk factor for the development of atherosclerosis. The extensive use of
lipid-lowering agents, such as statins, has led to a marked reduction ineNOS, endothelial nitric oxide
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.Open access under CC BY-NC-SA licenthe number of cardiovascular events in recent years. Despite this
achievement, many patients with cardiovascular disease cannot be ef-
fectively treated with the use of statins alone [2]. Therefore, it is neces-
sary to develop new therapeutics for these patients.
Probucol (PB) not only is a lipid-lowering agent but also possesses
strong antioxidant properties against low-density lipoproteins (LDL).
To date, many studies have shown that PB exhibits anti-atherogenic ef-
fects [3]. It has been shown that PB exerts its anti-atherogenic effects
through diverse molecular mechanisms, including anti-inﬂammatory
effects, the inhibition of smoothmuscle cell (SMC) proliferation, the en-
hancement of the expression of scavenger receptor class B type I, and
the improvement of the functions of high-density lipoproteins (HDL)
to enhance reverse cholesterol transport [4–7].
Cilostazol (CZ) is a speciﬁc phosphodiesterase type III inhibitor
that is currently used for the treatment of thrombotic vascular dis-
ease due to its anti-platelet aggregation functions [8]. As an anti-
thrombotic drug, CZ is a preferred alternative to aspirin because CZ
has fewer side effects, such as increased bleeding time [9]. Previousse. 
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[10]. In vitro studies have revealed that CZ suppresses the production
of intracellular reactive oxygen species (ROS) [11], and increases the
production of nitric oxide (NO) [12]. Furthermore, CZ promotes re-
verse cholesterol transport and inhibits the inﬂammation and prolif-
eration of SMCs [13–16].
Because both PB and CZ have anti-atherogenic effects, we hypothe-
sized that the combination of minimal doses of PB and CZmay exert ad-
ditional beneﬁcial effects and may result in a greater athero-protective
response. If so, this combinatorial therapy may provide a novel strategy
for the treatment and prevention of atherosclerosis for those patients
who cannot be effectively treated by statins. In the current study, we
compared the anti-atherogenic effects of the combination of PB and
CZ in cholesterol-fed rabbits with those obtained with either PB or CZ
alone. Our results showed that the combination of PB and CZ clearly re-
duced the aortic atherosclerotic lesion area, and markedly inhibited
macrophage (MФ) accumulation and SMC proliferation in the lesions
compared with the vehicle group. The anti-atherogenic effects of PB
andCZmay be collectivelymediated bymultiplemechanisms, including
anti-oxidant effects, anti-inﬂammatory effects, a decrease in the plasma
lipid levels, an increase in the levels of NO, and the maintenance of the
endothelial protein S-nitrosylation.
Materials and Methods
Animals and Diets
Fifty-ﬁve Japanese white rabbits (four-month old males) were sup-
plied by Wuhan Institute of Biological Products Co., Ltd., Wuhan,
China, and were fed a 0.5% cholesterol diet for one week. Based on
their plasma total cholesterol (TC) levels (average 400 mg/dl), we se-
lected 40 rabbits, and these were subsequently divided into the follow-
ing groups: (1) vehicle group; (2) 0.3% PB group; (3) 0.3% CZ group; and
(4) 0.3% PB and 0.3% CZ group. All of the rabbits were fed a cholesterol
diet containing 0.3% cholesterol for 16 weeks. PB and CZ were donated
by Otsuka Pharmaceutical Co., Ltd. (Tokushima, Japan), and were
added directly to the cholesterol diet. All of the rabbits were fed a re-
stricted diet of 100 g/rabbit/day, and the animals were given free access
to water throughout all of the experiments. The animal experiments
were approved by the Laboratory Animal Administration Committee
of Xi’an Jiaotong University and performed according to the Guidelines
for Animal Experimentation of Xi’an Jiaotong University and the Guide
for the Care andUse of Laboratory Animals published by theUSNational
Institutes of Health (NIH Publication NO. 85–23, revised 2011).
Determination of Plasma Lipid Levels and Other Biochemical Parameters
Blood samples were collected from the ear artery of each rabbit
after the animals had fasted for 16 hours. The plasma levels of TC,
HDL cholesterol (HDL-C), and LDL cholesterol (LDL-C) were mea-
sured every two or four weeks using commercially available TC
assay kits (cholesterol oxidase colorimetry), HDL-C assay kits
(phosphotungstic acid-magnesium precipitation colorimetry) and
LDL-C assay kits (polyethylene sulfuric acid precipitation colorime-
try), respectively, (Biosino Bio-technology and Science Inc., Beijing,
China). The LDLs were precipitated and isolated using the polyethyl-
ene sulfuric acid method according to the manufacturer’s instruc-
tions. The plasma lipid levels are presented as the calculated area
under the curve (AUC) [17]. The levels of plasma CRPwere quantiﬁed
using an ELISA assay kit(Immunology Consultants Laboratory, Inc.,
Newberg, OR, USA). The levels of plasma superoxide dismutase
(SOD), malondialdehyde (MDA), and NO were measured using xan-
thine oxidase assay, thiobarbituric acid assay, and nitrate reductase
assay kits (Najing Jiancheng Bioengineering Institute, Nanjing, China),
respectively.Quantiﬁcation of Gross Atherosclerotic Lesions
At the end of the experimental period, all of the rabbits were
sacriﬁced through the intravenous injection of an overdose of sodium
pentobarbital solution. The aortas were isolated, opened and ﬁxed in
formalin. The aortic trees were stained with Sudan IV, as previously de-
scribed [18,19] and photographed using a digital camera and the en face
aortic sudanophilic area was quantiﬁed using the Lumina Vision V3.0
image analysis software (Mitani Co, Tokyo, Japan).
Histology and Immunohistochemistry
For histological analysis, the aortic arch of each rabbitwas cut into 10
segments, as previously described, and stained with hematoxylin and
eosin and with Elastica van Gieson [20]. The microscopic lesion area
was calculated using the image analysis software described above.
Moreover, the serial sections were immunohistochemically stained
with antibodies (Abs) against MФ (RAM11; Dako, Carpinteria, CA,
USA) and SMC (α-actin; Thermo Fisher Scientiﬁc Pierce, Rockford, IL,
USA), and then with peroxidase-conjugated anti-IgG antibody (Santa
Cruz Biotechnologies, Inc., Santa Cruz, CA, USA). Aminoethyl carbazole
(Beijing Zhongshan Biotechnology, Beijing, China) was used as a sub-
strate and the slides were counter-stained with hematoxylin. The num-
bers of MФ and SMC in the lesions were quantiﬁed as the positive area
obtained through immunohistochemical staining, using image analysis
software.
In Vitro Experiments
Cell Culture
HUVECs were isolated from human umbilical cords using 0.1% (w/v)
collagenase (Gibco/Invitrogen, Carlsbad, CA, USA). The cells were cul-
tured at 37 °C in a humidiﬁed atmosphere of 5% CO2 and 95% air in
M199 medium (Gibco/Invitrogen, Carlsbad, CA, USA) supplemented
with 20% fetal bovine serum (Gibco/Invitrogen, CA, Carlsbad, USA),
100 U/ml penicillin (Life Technologies, Carlsbad, CA, USA), 100 μg/ml
streptomycin (Life Technologies, Carlsbad, CA, USA), 100 μg/ml heparin
sodium (Fluka/Sigma-Aldrich, St Louis, MO, USA), and 1% (v/v) endothe-
lial cell growth supplement (Sciencell Research Laboratories, Carlsbad,
CA, USA) [19]. The HUVECs were treated with PB (50 μM), CZ
(100 μM), or both PB (50 μM) and CZ (100 μM) for 24 hours in the pres-
ence of oxidized-LDL (ox-LDL, 50 μg/ml). The supernatant NO levels
were measured through a nitrate/nitrite assay and the protein S-
nitrosylation of the HUVECs was detected through immunoﬂuorescence
for S-nitrosocysteine and a biotin switch assay. Umbilical cords were
obtained from participants who provided informed consent. The proto-
col was approved by the Xi'an Jiaotong University Second Afﬁliated Hos-
pital Ethics Committee, and the investigation also conformed to the
principles outlined in the Declaration of Helsinki for the use of human
tissues or subjects.
Nitrate/Nitrite Assay
The amount of NO in the conditionedmediumwas determined by
estimating the total concentration of nitrate/nitrite using a nitrate/
nitrite colorimetric assay kit (Jiancheng Technology Ltd., Nanjing,
China).
Immunoﬂuorescent Staining
The HUVECs were ﬁxed with 4% paraformaldehyde for 15 minutes
at room temperature. The cells were treated with permeabilization so-
lution containing 3% (w/v) bovine serum albumin fraction V and 0.1%
(v/v) Triton X-100 for 15 minutes and with 5% horse serum for 30 mi-
nutes and, then incubated with an anti-nitrosocysteine antibody
(Abcam, Cambridge, MA, USA) overnight at 4 °C. After incubation with
a FITC-IgG antibody (Santa Cruz Biotechnologies, Santa Cruz, CA, USA)
for 30 minutes at room temperature, the cells were visualized with a
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rescence intensity was determined using the Lumina Vision V3.0 image
analysis software (Mitani Co, Tokyo, Japan).
Detection of S-Nitrosylated Proteins Using the Biotin Switch Assay
The HUVECs were lysed in HEN buffer (100 mM Hepes, 1 mM
EDTA, and 0.1 mM neocuproine, pH 8.0) containing 1% (w/v) SDS,
1 mM PMSF, and protease inhibitors (Roche, Basel, Switzerland).
The proteins extracted from the HUVECs were quantiﬁed using a
BCA assay kit (Thermo Fisher Scientiﬁc Pierce, Rockford, IL, USA).
Equal amounts of protein were incubated with HEN buffer containing
2.5% (w/v) SDS and 0.1% (v/v) S-methyl methanethiosulfonate (Fluka/
Sigma- Aldrich, St Louis, MO, USA) at 50 °C in the dark for 20 minutes.
The extracts were precipitated with cold acetone. The proteins were
re-suspended in HEN buffer with 1% SDS. The S-nitrosothiols were
decomposed by the addition of ascorbate followed by incubation with
2.5 mg/ml biotin-HPDP (Thermo Fisher Scientiﬁc Pierce, Rockford, IL,
USA) for 1 hour at room temperature. The samples from the biotin
switch assay were separated on 12% SDS-polyacrylamide gels, trans-
ferred to PVDFmembranes (EMDMillipore, Billerica, MA, USA), and in-
cubated overnight at 4 °C with speciﬁc antibodies, including a
horseradish peroxidase-conjugated anti-biotin antibody(Cell Signaling
Technology, Danvers, MA, USA) and, an anti-β-actin antibody (Abcam,Fig. 1. Effect of combinatorial treatment of probucol and cilostazol on the levels of plasma chole
cholesterol (B), and high-density lipoprotein cholesterol (C) levels were measured, and the are
each group; * p b 0.05 and **p b 0.01. Notations: AUC: area under the curve; CZ: cilostazol; HD
probucol; TC: total cholesterol.Cambridge, MA, USA). After this incubation, themembranes were incu-
bated with a horseradish peroxidase-conjugated IgG antibody (Thermo
Fisher Scientiﬁc Pierce, Rockford, IL, USA) and detected through en-
hanced chemiluminescence using a SuperSignal West Pico Substrate
kit (Thermo Fisher Scientiﬁc Pierce, Rockford, IL, USA). The protein
bands were detected using the Chemi Doc-it HR 410 imaging system
(Ultra-Violet Products. Ltd., Upland, CA, USA) [22].
Statistical Analysis
All of the values are expressed as the mean ± SEM. The statistical
analyses involved analysis of variance (ANOVA) followed by Tukey’s
test and were performed using the SAS software (SAS, release 9.1, SAS
Institute Japan). In all cases, differences with a P value of less than
0.05 were considered signiﬁcant.
Results
Analysis of Plasma Lipids
There was no difference in the food intake, body and fat weight, and
triglyceride levels between the four groups (data not shown). The plas-
ma TC levels expressed by AUC were signiﬁcantly decreased in thesterol in cholesterol-fed rabbits. The plasma total cholesterol (A), low-density lipoprotein
a under the curve was calculated. The data are expressed as the mean ± SEM. n = 10 for
L-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; PB:
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(Fig. 1A right). Similarly, the plasma LDL-C levels were signiﬁcantly de-
creased in the PB + CZ group (41%, p b 0.05) compared with the vehi-
cle group (Fig. 1B right). The administration of PB alone or in
combination with CZ also led to a decrease in the plasma HDL-C levels
throughout the experiment (Fig. 1C left). The HDL-C levels were re-
duced by 58% (p b 0.01) and 50% (p b 0.01) in the PB and PB + CZ
groups, respectively, compared with the vehicle group (Fig. 1C right).
Treatment with CZ alone did not change the lipid levels throughout
the experiment.
Analysis of Aortic Atherosclerosis
Some of the drug treatments led to a reduction in the gross aortic
atherosclerosis: the atherosclerosis in the PB + CZ and the PB groups
were 70% and 56% compared with the vehicle group (Fig. 2A). More-
over, these treatments also led to a reduction in the lesion size in all
parts of the aortic trees compared with the vehicle group (arch: 59%
in the PB + CZ and 49% in the PB; thoracic aorta: 74% in the PB + CZ
and 65% in the PB; abdominal aorta: 76% in the PB + CZ and 62% in
the PB) (Fig. 2B).
The histological examinations revealed that the lesions in all of the
groups mainly consisted of fatty streaks. The administration of PB alone
or in combination with CZ resulted in a signiﬁcant decrease in the size
of the lesions (69% and 65% reduction, respectively) compared with the
vehicle group (Fig. 3 A and B). Moreover, the immunohistochemicalFig. 2. Effects of probucol and cilostazol on the aortic atherosclerotic lesion area in cholesterol-fe
in different parts of the aorta (B). The data are expressed as the mean ± SEM. n = 10 for eachstaining revealed that the proportion ofMФ and SMCswere signiﬁcantly
reduced, (by 64% and 54%, respectively), in the group treated with
PB + CZ compared with the vehicle group (Fig. 3 A and B).
Plasma Inﬂammatory and Lipid Peroxidation Markers and NO Levels
To evaluate whether PB and CZ affected the plasma inﬂammatory
markers and lipid peroxidation markers, we measured the levels of
CRP, MDA and SOD. As shown in Fig. 4, all of the treatments reduced
the levels of plasma CRP compared with the vehicle group (84% in the
PB + CZ group, 78% in the PB group and 55% in the CZ group; Fig. 4A).
The same trend was observed with the levels of plasma MDA (41% in
the PB + CZ group, 31% in the PB group and 28% in the CZ group;
Fig. 4B). However, all of the treatments increased the levels of plasma
SOD (by 2.1-fold in the PB + CZ; 1.9-fold in the PB group; 1.7-fold in
the CZ group) compared with that observed in the vehicle group
(Fig. 4C). In addition, we measured the plasma levels of NO and found
that PB + CZ increased the levels of plasma NO compared with the ve-
hicle group (Fig. 4D).
Effects of PB and CZ Treatment on Protein S-Nitrosylation of HUVECs
To investigate the molecular mechanisms responsible for the
anti-atherogenic effects of PB and CZ, we studied their effects on
NO production and S-nitrosylation of proteins using cultured HUVECs.
The oxidized LDLs signiﬁcantly inhibited the levels of NO and thed rabbits. The aortic treeswere stainedwith Sudan IV (A) and lesion areas were calculated
group; * p b 0.05 and **p b 0.01. Notations: CZ: cilostazol; PB: probucol.
Fig. 3.Histological analysis of aortic atherosclerosis. Representativemicrographs of the intimal lesions and cellular components (A)morphometric analysis of the lesion area, and percent-
age of MФ and SMCs in these lesions (B). The data are expressed as the mean ± SEM. n = 10 for each group; *p b 0.05. Notations: CZ: cilostazol; EVG: Elastica van Gieson; HE: hema-
toxylin and eosin; MФ: macrophage; PB: probucol; SMC: smooth muscle cells.
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CZ alone or PB + CZ signiﬁcantly protected the oxLDL-induced inhibi-
tion of both NO production (Fig. 5D) and protein S-nitrosylation
(Fig. 5A, B, and C). These results show that this protective effect is great-
er when PB and CZ are combined (Fig. 5).
Discussion
Although many previous studies have demonstrated that either PB
or CZ may have anti-atherogenic effects, it is not clear whether the si-
multaneous administration of these two drugs at low doses may have
any additional beneﬁcial effects in terms of athero-protection. In the
current study, we found that the combination of PB and CZ exerted an
anti-atherogenic effect. PB inhibits atherosclerosis through several mo-
lecularmechanisms that include lipid-lowering, anti-inﬂammation, and
anti-oxidization [23–25]whereas CZ protects against atherosclerosis in-
dependent of its lipid-lowering effects [10]. When the two drugs are
combined, their anti-atherogenic effects were enhanced. However, it
appears that PB and CZ exhibit complementary effects. First, the levels
of plasma NO were dramatically increased after PB + CZ treatment,
and this effect was not signiﬁcantly different from that observed afterthe administration of either of the drugs alone. This ﬁnding suggests
that the combinatorial anti-atherogenic effect is partly mediated
through an improvement in the vascular functions by increasing the
levels of NO and endothelial protein S-nitrosylation and to the effects
elicited by each of the drugs alone.
It should be noted that the reduction in the lesion area observed in
the PB + CZ group was accompanied by a signiﬁcant reduction in the
numbers of Mϕ and SMCs in the lesions, which was not evident in the
other two groups. Thus, the combination of PB and CZ may exert a po-
tent anti-inﬂammatory effect, as shown by the reduced levels of CRP
in this group. Although PB treatment led to a decrease in the levels of
plasma HDL-C, this result does not necessarily imply that lower-HDL-C
levels are detrimental because PB modulates the properties of HDL par-
ticles [7], promotes reverse cholesterol transport through the activation
of the cholesteryl ester transfer protein [4], up-regulates the expression
of hepatic scavenger receptor class B type I [6], and suppresses hepatic
ATP-binding cassette transporter A1 [26].
Oxidative stress is thought to play an important role in the patho-
genesis of atherosclerosis [27,28]. In the current study, the combination
of PB and CZ increased the activity of plasma SOD and decreased the
levels of MDA, which suggests that the combinatorial administration
Fig. 4. Effects of probucol and cilostazol on oxidative stress, inﬂammation, and endothelial
cell functions in cholesterol-fed rabbits. The plasma C-reactive protein (A), malonaldehyde
(B), superoxide dismutase (C), and nitric oxide (D) levels were measured after16 weeks of
treatment. The data are expressed as the mean ± SEM. n = 10 for each group; * p b 0.05
and **p b 0.01. Notations: CZ: cilostazol; CRP: C-reactive protein; MDA: malonaldehyde;
NO: nitric oxide; PB: probucol; SOD: superoxide dismutase.
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enine dinucleotide phosphate oxidase-dependent superoxide for-
mation [29], and PB has been reported to effectively inhibit the
production of oxygen free radicals [30]. The combination of both
drugs synergistically reduced the nicotinamide adenine dinucleotideFig. 5. Effects of probucol (PB) and cilostazol (CZ) on protein S-nitrosylation in HUVECs. HUVEC
(100 μM) for 24 hours with ox-LDL (50 μg/ml). The S-nitrosylated proteins in intact cells were
lysates byWestern blotting using the biotin switch method (C). The NO levels were measured
experiments. * p b 0.05 and **p b 0.01. Notations: CZ: cilostazol; NO: nitric oxide; PB: probucophosphate-dependent superoxide formation and the intracellular
ROS production [31,32].
The reduction in the bioavailability of NO is a characteristic of endo-
thelial dysfunction which is a key step in all stages of atherosclerosis
[33]. It has been shown that the biological functions of NO act via
cGMP-dependent and cGMP-independent pathways through the modiﬁ-
cation of proteins by S-nitrosylation. In endothelial cells, S-nitrosylation is
able to inﬂuence cellular metabolic processes, and to regulate many
important cellular and vascular functions, such as inﬂammation
[34], apoptosis [35], permeability [36], migration [37], cell growth
[38], and vascular stiffness [39]. A previous study showed that statins
can exert pleiotropic vasculoprotective effects via the S-nitrosylation
of thioredoxin [40]. In the present in vivo study, the PB + CZ group
showed signiﬁcantly increased plasma levels of NO. CZ promotes
NO production by the activation of eNOS in endothelial cells
[12,41]. Moreover, PB enhances NO bioactivity through the up-
regulation eNOS expression [42]. Furthermore, the combination of
PB and CZ leads to the up-regulation of the expression of eNOS rather
than the acute activation of eNOS through a phosphorylation modiﬁ-
cation [43]. In addition, we investigated whether the effect on the
levels of NO in HUVECs by CZ, PB, and CZ + PB induced damage by
ox-LDL. The results suggest that PB, CZ, and PB + CZ can up-
regulate the ox-LDL-inhibited levels of NO in vitro. This effect was
more apparent with the combination of PB and CZ. Moreover, all of
the treatment groups were protected against the oxLDL-induced S-
nitrosylation of proteins compared with the vehicle group, but these ef-
fects were more pronounced in the PB + CZ group.
In conclusion, we demonstrated that the combination of low
doses of PB with CZ exhibited enhanced atheroprotective effects.
These effects are attributed to diverse mechanisms, including lipid-
lowering, anti-oxidization, anti-inﬂammation, up-regulation of the
levels of NO and endothelial protein S-nitrosylation. These ﬁndings
may provide new clues for the development of new therapeutics
aimed at treating atherosclerosis.s were incubated with PB (50 μM), CZ (100 μM), or the combination of PB (50 μM) and CZ
detected by immunoﬂuorescence for nitrosocysteine (A and B) and determined in the cell
by the nitrate/nitrite assay (D). The data represent the mean ± SEM of three independent
l.
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